No Data
No Data
Maiwei Biotech (688062.SH): Net loss of 206 million yuan in the first quarter
Gelonghui, April 29丨Maiwei Biotech (688062.SH) released its report for the first quarter of 2024, achieving operating income of 67.551 million yuan, an increase of 1572.42% over the previous year; net profit attributable to shareholders of listed companies - 206 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 218 million yuan, and basic earnings per share of 0.51 yuan.
Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progre
Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progressing well. (Mainichi Keizai Shimbun)
Maiwei Bio-U (688062): NECTIN-4 ADC multi-indication rapid clinical promotion
Product sales are growing rapidly. Maiwei Biotech achieved revenue of 128 million yuan (+361%) in 2023. The sharp increase in revenue was mainly due to the company's 9MW3011 project's external authorization and receipt of a down payment of 10 million US dollars
Maiwei Biology (688062): Analogs are entering the harvest period and the development of new drugs is being promoted efficiently
Core view: 9MW2821 is progressing smoothly and is the first drug with the same target to disclose CC and EC efficacy data. According to the company's 2023 annual report, 9MW2821 was treated with platinum chemotherapy and anti-PD- (L) 1 treatment
Maiwei Biotech (688062): ADC released multiple data and commercialization of similar drugs in China progressed smoothly
Performance: The company released its annual report on April 9, 2024. The 2023 revenue was 128 million yuan, technical service revenue was 85.5953 million yuan, pharmaceutical sales revenue was 42.09 million yuan, and R&D investment was 8.3 million yuan
Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is prog
Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is progressing steadily, and emerging markets continue to be developed; 3) the research pipeline is progressing efficiently, and multiple indications of Nectin-4ADC shows positive curative effects; 4) It has a mature production transformation system and forward-looking layout of large-scale commercial production capacity. (Mainichi Keizai Shimbun)
No Data